Accelevir offers highly quantitative assays to support HIV-1 cure programs. We are currently funded to support investigator-initiated clinical trial measurements through the National Institute of Allergy and Infectious Diseases Resource Cooperative Agreement.
Our journey started in collaboration with experts from Johns Hopkins University, key thought leaders and customers within the HIV-1 cure community. Our commitment to customer needs defines our expanding assay portfolio with the goal of developing a fit for purpose approach.
On the lab-side of Accelevir, we are dedicated to detecting with very high quality of science – we detect rare targets to help solve the ability for early identification of disease.
How We Can Help
Provide critical measurements within a CLIA environment.
Combine cutting edge molecular technologies that include digital PCR, single target culture techniques, high fidelity sequencing and data driven analytics.
Integrate strong science with customer focused company ethos.
Albine Martin, PhD
Co-Founder & Managing Director
Gregory Laird, PhD
Co-Founder & Head of Research and Development
Mian Cai, PhD
Hannah MacLeod, PhD
Quality & Laboratory Operations
Qiuyan Ma, PhD
Willam Clarke, PhD
Clinical Business Development
Douglas Toal, PhD, D(ABBM)
Quality Systems Specialist
Kristin Mullins, PhD, NRCC